Compare Merck & Co., Inc. (MRK) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Invesco Solar ETF — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Invesco Solar ETF trades at $53.51. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Invesco Solar ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| MRK | TAN | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Sector/Thematic |
52-Week High | $129.52 | $73.95 |
52-Week Low | $77.60 | $36.07 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
TAN trades at $52.69, down 2.24% amid broad market weakness, with technical indicators signaling a bearish trend. The ETF faces headwinds from lower oil prices and a strong US dollar, though long-term growth prospects remain tied to rising electricity demand from data centers and AI. Recent news highlights both opportunities in the energy transition and risks from regulatory delays and geopolitical tensions affecting solar investments.
The outlook for TAN is cautious near-term due to technical deterioration and valuation concerns, but sustained demand for clean energy offers long-term potential. Key risks include policy uncertainty, competition from nuclear energy, and reliance on large-scale solar projects. Investors should weigh volatility against the structural shift toward renewable infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
